

---

## ExpreS<sup>2</sup>ion publishes filmed scientific interview on the cVLP COVID-19 vaccine development

**ExpreS<sup>2</sup>ion Biotech Holding AB's affiliate ExpreS<sup>2</sup>ion Biotechnologies ApS ("ExpreS<sup>2</sup>ion") announces that a filmed scientific talk on the development of the cVLP COVID-19 vaccine has been published on the company's website. The video features Dr. Max M Søgaaard from ExpreS<sup>2</sup>ion and Dr. Ali Salanti from ExpreS<sup>2</sup>ion's joint venture and development partner AdaptVac.**

In the interview, Drs. Max M Søgaaard and Ali Salanti talk about the rapid development process of the cVLP COVID-19 vaccine, and how it was made possible through a great collaborative effort between several industry entities and financiers. They also discuss the possibility of utilising their experiences from the cVLP COVID-19 vaccine project to speed up the development process of other pipeline projects.

The video can be viewed by following [this link to ExpreS<sup>2</sup>ion's website](#).

This informative scientific interview was produced by cell counting and analysis company [Chemometec](#), and it is published on ExpreS<sup>2</sup>ion's website with their permission.

### **Certified Adviser**

Svensk Kapitalmarknadsgranskning AB  
Telefon: +46 11 32 30 732  
E-post: [ca@skmg.se](mailto:ca@skmg.se)

### **For further information about ExpreS<sup>2</sup>ion Biotech Holding AB, please contact:**

Bent U. Frandsen, CEO  
Telephone: +45 4256 6869  
E-mail: [buf@expres2ionbio.com](mailto:buf@expres2ionbio.com)

---

### **About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. ExpreS<sup>2</sup>ion has developed a unique technology platform, ExpreS<sup>2</sup>, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS<sup>2</sup> is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS<sup>2</sup>ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com) and [www.adaptvac.com](http://www.adaptvac.com).